Alnylam Pharmaceuticals
ALNY
258 hedge funds and large institutions have $5.26B invested in Alnylam Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 93 increasing their positions, 89 reducing their positions, and 53 closing their positions.
37% more call options, than puts
Call options by funds: $59.2M | Put options by funds: $43.1M
4% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 89
7% less funds holding
Funds holding: 278 → 258 (-20)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
32% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 53
33% less capital invested
Capital invested by funds: $7.86B → $5.26B (-$2.61B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$78.9M |
| 2 |
Jennison Associates
New York
|
+$58.7M |
| 3 |
UIM
USS Investment Management
London,
United Kingdom
|
+$30.7M |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$28.1M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$27.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$86M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$43.5M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$38.5M |
| 4 |
CCI
Columbus Circle Investors
|
-$28.5M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$21.2M |
ALNY Hedge Fund Activity: Q3 2015 in Review
258 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2015, worth a combined $5.26B — down 33% from $7.86B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of ALNY and 36 opened new positions — a net loss of 17 holders — while 89 trimmed existing stakes and 93 added.
The largest buyer was Wellington Management Group, adding an estimated $78.9M. The largest seller was Artisan Partners, cutting an estimated $86M.
- 258 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2015, down from 278 in Q2 2015.
- Funds reported $5.26B of Alnylam Pharmaceuticals stock for Q3 2015, down 33% quarter-over-quarter.
- 36 funds opened new Alnylam Pharmaceuticals positions in Q3 2015 and 53 closed out, a net change of -17 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2015 was Wellington Management Group, an estimated $78.9M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2015 was Artisan Partners, an estimated $86M sold.
Based on aggregated 13F filings for Q3 2015.